uniQure N.V. (QURE)

NASDAQ: QURE · Real-Time Price · USD
7.32
-0.12 (-1.54%)
Nov 8, 2024, 10:39 AM EST - Market open
-1.54%
Market Cap 358.66M
Revenue (ttm) 28.59M
Net Income (ttm) -239.50M
Shares Out 48.70M
EPS (ttm) -4.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 95,619
Open 7.44
Previous Close 7.43
Day's Range 7.17 - 7.45
52-Week Range 3.73 - 11.35
Beta 0.90
Analysts Buy
Price Target 17.00 (+130.82%)
Earnings Date Nov 5, 2024

About QURE

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2007
Employees 480
Stock Exchange NASDAQ
Ticker Symbol QURE
Full Company Profile

Financial Performance

In 2023, uniQure's revenue was $15.84 million, a decrease of -85.12% compared to the previous year's $106.48 million. Losses were -$308.48 million, 143.3% more than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for QURE stock is "Buy." The 12-month stock price forecast is $17.0, which is an increase of 130.82% from the latest price.

Price Target
$17.0
(130.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington's disease ~

3 days ago - GlobeNewsWire

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

24 days ago - GlobeNewsWire

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs...

6 weeks ago - GlobeNewsWire

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

3 months ago - GlobeNewsWire

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend...

3 months ago - Seeking Alpha

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegener...

3 months ago - GlobeNewsWire

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~

3 months ago - GlobeNewsWire

What Led To A 150% Rise In UniQure Stock In A Week?

uniQure stock (NASDAQ: QURE), a gene therapy company, has seen a stellar 150% rise in a week, faring significantly better than its peer – Editas Medicine stock –, up 12%. This massive rise in QURE sto...

4 months ago - Forbes

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

uniQure reported positive interim results across phase 1/2 studies, using AMT-130 for the treatment of patients with Huntington's Disease, leading to an 80% slowing of disease progression. The company...

4 months ago - Seeking Alpha

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the compo...

4 months ago - GlobeNewsWire

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

~ Proposed divestiture streamlines uniQure's focus and represents an important milestone in its ongoing effort to significantly reduce operating expenses ~

4 months ago - GlobeNewsWire

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Strategic acquisition will enable Genezen to deliver late-phase and commercial gene therapy development and manufacturing services to customers around the world. BOSTON and INDIANAPOLIS , July 1, 2024...

4 months ago - PRNewsWire

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington's dise...

5 months ago - GlobeNewsWire

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

~ On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical update from the Phase I/II trials in mid-2024 ~ ~ Clinical trial initiation for Fabry disease ...

6 months ago - GlobeNewsWire

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

~ Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington's disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interacti...

9 months ago - GlobeNewsWire

uniQure: The Valuation Got More Attractive

uniQure is valued here as a pre-revenue company assessing its liquidation value, value of potential cash flows from HEMGENIX sales and estimating the worth of its future R&D efforts. In 2023, uniQure ...

10 months ago - Seeking Alpha

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history  ...

11 months ago - GlobeNewsWire

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

HEMGENIX® is the first and only gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia B and to show sustained efficacy and safety at three years post-tre...

11 months ago - PRNewsWire

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

1 year ago - GlobeNewsWire

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- uniQure N.V.

1 year ago - GlobeNewsWire

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

~ Announced FDA clearance of Investigational New Drug (IND) application for AMT-260 in  refractory mesial temporal lobe epilepsy ~

1 year ago - GlobeNewsWire

CSL and uniQure Win 2023 Prix Galien USA Award

HEMGENIX®, the first and only FDA-approved gene therapy for adults with hemophilia B, wins for Best Product for Rare/Orphan Diseases KING OF PRUSSIA, Pa. and LEXINGTON, Mass.

1 year ago - PRNewsWire

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...

1 year ago - GlobeNewsWire

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

UniQure N.V. QURE, -4.74%, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it's planning a strategic overhaul that will cut 28% of its work...

1 year ago - Market Watch

Gene therapy maker UniQure to cut about 20% of workforce

Dutch gene therapy maker uniQure said on Thursday it would cut about 20% of its total workforce, or about 114 jobs, and end investments in more than half of its research and technology projects to red...

1 year ago - Reuters